Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Federal Trade Commission
Queensland Health
Covington
QuintilesIMS
Express Scripts
Merck
US Army
Dow

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,338,479

« Back to Dashboard

Which drugs does patent 8,338,479 protect, and when does it expire?

Patent 8,338,479 protects LUMIGAN and is included in one NDA.

This patent has thirty-two patent family members in twenty-one countries.
Summary for Patent: 8,338,479
Title:Enhanced bimatoprost ophthalmic solution
Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
Inventor(s): Chang; Chin-Ming (Tustin, CA), Chang; James N. (Newport Beach, CA), Schiffman; Rhett M. (Laguna Beach, CA), Jordan; R. Scott (Trabuco Canyon, CA), Chang-Lin; Joan-En (Tustin, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:12/351,383
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,338,479
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,338,479

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up Y A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,338,479

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,933,127 Enhanced bimatoprost ophthalmic solution ➤ Sign Up
8,299,118 Enhanced bimatoprost ophthalmic solution ➤ Sign Up
8,933,120 Enhanced bimatoprost ophthalmic solution ➤ Sign Up
7,851,504 Enhanced bimatoprost ophthalmic solution ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Colorcon
US Army
Argus Health
Julphar
Express Scripts
Farmers Insurance
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.